Vivani Medical, Inc. is a clinical-stage biopharmaceutical company, developing miniature, ultra-long-acting drug implants. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in overweight individuals. Its pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.
Símbolo de cotizaciónVANI
Nombre de la empresaVivani Medical Inc
Fecha de salida a bolsaDec 05, 2014
Director ejecutivoMendelsohn (Adam)
Número de empleados42
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 05
Dirección1350 S. Loop Road
CiudadALAMEDA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94502
Teléfono14155068462
Sitio Webhttps://vivani.com/
Símbolo de cotizaciónVANI
Fecha de salida a bolsaDec 05, 2014
Director ejecutivoMendelsohn (Adam)
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos